Achaogen Announces Data on Epidemiological Trends of Carbapenem-Resistant Enterobacteriaceae at SHEA Spring 2017 Conference
29 mars 2017 08h01 HE
|
Achaogen Inc.
-- Data suggest high prevalence of CRE with rapid rate of increase -- -- Company’s late-stage candidate, plazomicin, may provide an important new option in treating MDR infections, including those...
Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
14 mars 2017 16h01 HE
|
Achaogen Inc.
Achieved positive results in Phase 3 EPIC and CARE clinical trials of plazomicin; NDA submission planned for the second half of 2017 Unveiled new orally-administered antibacterial clinical candidate,...
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2016 Financial Results on March 14, 2017
06 mars 2017 08h00 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing novel antibacterials addressing...
Achaogen to Present at the Cowen and Company 37th Annual Health Care Conference
02 mars 2017 16h01 HE
|
Achaogen Inc.
-- Company presentation scheduled for March 7th, 2017 at 9:20 a.m. ET -- SOUTH SAN FRANCISCO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical...
Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company's R&D Day
01 mars 2017 16h01 HE
|
Achaogen Inc.
-- Plazomicin NDA submission planned for the second half of 2017 -- -- Plan to initiate clinical trial of orally-administered antibacterial candidate for ESBL+ infections, C-Scape, in 2017 -- --...
Achaogen Announces New Employment Inducement Grants
28 févr. 2017 08h00 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing...
Achaogen Adds Janet Dorling as Chief Commercial Officer
27 févr. 2017 09h15 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing...
Achaogen Announces Leadership Promotions
23 févr. 2017 16h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing...
Achaogen Announces Achievement of a Key Milestone in Developing a Plazomicin Assay to Support Therapeutic Drug Management (TDM)
22 févr. 2017 16h01 HE
|
Achaogen Inc.
Strategic milestone achieved in TDM assay developmentThermo Fisher Scientific to develop and then commercialize its assay for measuring the concentration of plazomicinSOUTH SAN FRANCISCO, Calif., Feb....
Achaogen to Host R&D Day Focused on Advances and Opportunities in the Treatment of Resistant Gram-Negative Infections
15 févr. 2017 16h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing...